Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
Status:
Terminated
Trial end date:
2017-01-20
Target enrollment:
Participant gender:
Summary
Phase I/II study of ipilimumab concurrent ipilimumab and dabrafenib as first line treatment
in Stage III or IV melanoma.
Assessing safety of Ipilimumab and dabrafenib in combination. Also, assessing disease control
rates.